Zhan Gao

Zhan Gao

Auto-generated profile, based on publicly available information

Zhan Gao

Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Circulation: Heart Failure
Verified
Journal Article
Closed access
ZGZhan Gao
Zhan Gao
KRKalina J. Rossler
Kalina J. Rossler
HRHolden T. Rogers
Holden T. Rogers
ZGZachery Robert Gregorich
Zachery Robert Gregorich
TATimothy J. Aballo
Timothy J. Aballo
YGYing Ge
Ying Ge
BACKGROUND: Hypertrophic cardiomyopathy (HCM) has traditionally been regarded as a disease of the sarcomere; however, it is in the midst of a paradigm shift with growing recognition of contributions beyond the sarcomere to the heterogeneity of HCM phenotypes. Innovative approaches are essential to uncover novel determinants and mechanisms underlying this heterogeneity. Top-down proteomics has emerged as a powerful method for analysis of proteoforms—the myriad protein products arising from genetic variants, posttranslational modifications, and splicing isoforms from a single gene—offering a more precise lens to understand the disease heterogeneity in HCM. Yet, how proteoforms are altered on a global scale in HCM has not been investigated. METHODS: Global top-down proteomics was performed on myocardial samples from patients with advanced obstructive HCM and nonfailing controls. Specifically, serial protein extraction enabled by the photocleavable surfactant, 4-hexylphenylazosulfonate (Azo), was utilized to solubilize diverse categories of proteins from minimal tissue, including membrane proteins. Subsequently, high-sensitivity top-down mass spectrometry was used to detect and quantify proteoforms across various cellular compartments. RESULTS: Using this global top-down proteomics approach, we have detected ≈2000 proteoforms across disparate cellular compartments, including the sarcoplasmic reticulum, cytoskeleton, mitochondria, and nucleus, in advanced obstructive HCM tissues. Quantitative analysis uncovered significant alterations not only in sarcomeric but also cytoskeletal, mitochondrial, nucleosome, and sarcoplasmic reticulum proteoforms in HCM as compared with nonfailing controls. Notably, we have discovered a significant proteoform crosstalk among the sarcomere, sarcoplasmic reticulum, and cytoskeleton. Moreover, we have identified a previously unrecognized decrease in succinylated mitochondrial proteoforms as a critical feature of the advanced obstructive HCM proteoform landscape, alongside a marked reduction in acetylation of nucleosome proteins. CONCLUSIONS: This study represents the most comprehensive analysis of the proteoform landscape in HCM to date, uncovering pathways beyond the sarcomere that may contribute to HCM pathophysiology and identifying potential targets for development of therapeutic interventions.

4 September 2026 in Mass Spectrometry Reviews
Verified
Journal Article
Open access
PDF file
HRHolden T. Rogers
Holden T. Rogers
ZGZachery R. Gregorich
Zachery R. Gregorich
MGMegan S. Gant
Megan S. Gant
ZGZhan Gao
Zhan Gao
JCJulia Chamot‐Rooke
Julia Chamot‐Rooke
YGYing Ge
Ying Ge
The proteome is a dynamic landscape of proteoforms arising from genetic mutations, alternative splicing, and post‐translational modifications (PTMs), which collectively drive biological function and disease phenotypes. Mass spectrometry (MS)‐based proteomics has emerged as an essential technique for elucidating this molecular complexity. Although bottom‐up proteomics enables deep protein identification and quantification through peptide‐level analysis, it disrupts molecular connectivity and introduces a peptide‐to‐protein inference problem, which is suboptimal for proteoform analysis. Top‐down proteomics (TDP) offers a complementary approach by analyzing intact proteins, preserving molecular connectivity, and enabling direct characterization and quantification of proteoforms. This capability is increasingly vital for understanding heterogeneous human diseases. Here, we review the evolving role of TDP in biomedical research, highlighting studies that revealed proteoform‐level alterations, identified candidate biomarkers, and advanced our understanding of the roles of proteoforms in human diseases.

11 October 2025 in bioRxiv
Verified
Preprint
Open access
BKBoris Krichel
Boris Krichel
HCHsin-Ju Chan
Hsin-Ju Chan
LBLiam Bandura
Liam Bandura
ZGZhan Gao
Zhan Gao
MWMan-Di Wang
Man-Di Wang
YGYing Ge
Ying Ge
Protein kinases integrate cellular signals through complex phosphorylation cascades, yet resolving how chemical perturbations trigger and modulate these cascades in therapeutic targets remains a major challenge. Here, we dissect AMP-activated protein kinase (AMPK) proteoforms during activation through controlled biochemical reactions with a hybrid mass spectrometry (MS) approach integrating bottom-up MS for site-specific kinetics with top-down proteoform characterization. We reveal that AMPK phosphorylation proceeds through hierarchical cascades rather than binary switching, with dual entry points: canonical CaMKK2-mediated phosphorylation or allosteric activator PF-739 both triggering extensive autophosphorylation with α1-S496 showing highest kinetic priority. Proteoform-resolved analysis uncovers channeled β1-S24/25+S108 co-phosphorylation linking subcellular localization with allosteric responsiveness. Site-directed mutagenesis demonstrates CaMKK2 targets only α1-T183, with all other modifications arising through autophosphorylation. Phosphatase competition reveals asymmetric control where PP1A selectively removes activation-loop phosphorylation while autophosphorylation sites remain protected, establishing persistent regulatory states. Resolving AMPK’s temporal kinetics and proteoform architecture during activation enables a proteoform-centric understanding on kinase regulation.

4 September 2026 in Science Advances
Verified
Journal Article
Open access
BKBoris Krichel
Boris Krichel
HCHsin-Ju Chan
Hsin-Ju Chan
LBLiam Bandura
Liam Bandura
ZGZhan Gao
Zhan Gao
MWMan-Di Wang
Man-Di Wang
YGYing Ge
Ying Ge
Protein kinases integrate cellular signals through complex phosphorylation cascades, yet resolving how chemical perturbations trigger and modulate these cascades in therapeutic targets remains a major challenge. Here, we dissect adenosine 5′-monophosphate–activated protein kinase (AMPK) proteoforms during activation through controlled biochemical reactions with a hybrid mass spectrometry (MS) approach integrating bottom-up MS for site-specific kinetics with top-down proteoform characterization. We reveal that AMPK phosphorylation proceeds through hierarchical cascades rather than binary switching, with dual entry points: canonical calcium- and calmodulin-dependent protein kinase kinase 2 (CaMKK2)–mediated phosphorylation or allosteric activator PF-739 both triggering extensive autophosphorylation with α1-Ser496 (S496) showing the highest kinetic priority. Proteoform-resolved analysis uncovers channeled β1-Ser24/25 (S24/25) + Ser108 (S108) cophosphorylation linking subcellular localization with allosteric responsiveness. Site-directed mutagenesis demonstrates CaMKK2 targets only α1-Thr183 (T183), with all other modifications arising through autophosphorylation. Phosphatase competition reveals asymmetric control where PP1A selectively removes activation-loop phosphorylation while autophosphorylation sites remain protected, establishing persistent regulatory states. Resolving AMPK’s temporal kinetics and proteoform architecture during activation enables a proteoform-centric understanding on kinase regulation.